167 related articles for article (PubMed ID: 36413881)
1. Lipolysis-stimulated lipoprotein receptor-targeted antibody-drug conjugate demonstrates potent antitumor activity against epithelial ovarian cancer.
Kanda M; Serada S; Hiramatsu K; Funauchi M; Obata K; Nakagawa S; Ohkawara T; Murata O; Fujimoto M; Chiwaki F; Sasaki H; Ueda Y; Kimura T; Naka T
Neoplasia; 2023 Jan; 35():100853. PubMed ID: 36413881
[TBL] [Abstract][Full Text] [Related]
2. LSR Antibody Therapy Inhibits Ovarian Epithelial Tumor Growth by Inhibiting Lipid Uptake.
Hiramatsu K; Serada S; Enomoto T; Takahashi Y; Nakagawa S; Nojima S; Morimoto A; Matsuzaki S; Yokoyama T; Takahashi T; Fujimoto M; Takemori H; Ueda Y; Yoshino K; Morii E; Kimura T; Naka T
Cancer Res; 2018 Jan; 78(2):516-527. PubMed ID: 29187404
[TBL] [Abstract][Full Text] [Related]
3. Anti-lipolysis-stimulated lipoprotein receptor monoclonal antibody as a novel therapeutic agent for endometrial cancer.
Nagase Y; Hiramatsu K; Funauchi M; Shiomi M; Masuda T; Kakuda M; Nakagawa S; Miyoshi A; Matsuzaki S; Kobayashi E; Kimura T; Serada S; Ueda Y; Naka T; Kimura T
BMC Cancer; 2022 Jun; 22(1):679. PubMed ID: 35729527
[TBL] [Abstract][Full Text] [Related]
4. LSR promotes epithelial ovarian cancer cell survival under energy stress through the LKB1-AMPK pathway.
Takahashi Y; Serada S; Ohkawara T; Fujimoto M; Hiramatsu K; Ueda Y; Kimura T; Takemori H; Naka T
Biochem Biophys Res Commun; 2021 Jan; 537():93-99. PubMed ID: 33388415
[TBL] [Abstract][Full Text] [Related]
5. Tumor cell-expressed lipolysis-stimulated lipoprotein receptor negatively regulates T-cell function.
Funauchi M; Serada S; Hiramatsu K; Funajima E; Kanda M; Nagase Y; Nakagawa S; Ohkawara T; Fujimoto M; Suzuki Y; Ueda Y; Kimura T; Naka T
Int J Cancer; 2024 Feb; 154(3):425-433. PubMed ID: 37728485
[TBL] [Abstract][Full Text] [Related]
6. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
7. SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression.
Menderes G; Bonazzoli E; Bellone S; Black J; Altwerger G; Masserdotti A; Pettinella F; Zammataro L; Buza N; Hui P; Wong S; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
Gynecol Oncol; 2017 Jul; 146(1):179-186. PubMed ID: 28473206
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors.
McDermott MSJ; O'Brien NA; Hoffstrom B; Gong K; Lu M; Zhang J; Luo T; Liang M; Jia W; Hong JJ; Chau K; Davenport S; Xie B; Press MF; Panayiotou R; Handly-Santana A; Brugge JS; Presta L; Glaspy J; Slamon DJ
Clin Cancer Res; 2023 Jun; 29(11):2131-2143. PubMed ID: 36884217
[TBL] [Abstract][Full Text] [Related]
9. Anti-glypican-1 antibody-drug conjugate is a potential therapy against pancreatic cancer.
Nishigaki T; Takahashi T; Serada S; Fujimoto M; Ohkawara T; Hara H; Sugase T; Otsuru T; Saito Y; Tsujii S; Nomura T; Tanaka K; Miyazaki Y; Makino T; Kurokawa Y; Nakajima K; Eguchi H; Yamasaki M; Mori M; Doki Y; Naka T
Br J Cancer; 2020 Apr; 122(9):1333-1341. PubMed ID: 32152502
[TBL] [Abstract][Full Text] [Related]
10. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
[TBL] [Abstract][Full Text] [Related]
11. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
[TBL] [Abstract][Full Text] [Related]
12. Anti-Glypican-1 Antibody-drug Conjugate as Potential Therapy Against Tumor Cells and Tumor Vasculature for Glypican-1-Positive Cholangiocarcinoma.
Yokota K; Serada S; Tsujii S; Toya K; Takahashi T; Matsunaga T; Fujimoto M; Uemura S; Namikawa T; Murakami I; Kobayashi S; Eguchi H; Doki Y; Hanazaki K; Naka T
Mol Cancer Ther; 2021 Sep; 20(9):1713-1722. PubMed ID: 34224365
[TBL] [Abstract][Full Text] [Related]
13. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer.
Perrone E; Lopez S; Zeybek B; Bellone S; Bonazzoli E; Pelligra S; Zammataro L; Manzano A; Manara P; Bianchi A; Buza N; Tymon-Rosario J; Altwerger G; Han C; Menderes G; Ratner E; Silasi DA; Azodi M; Hui P; Schwartz PE; Scambia G; Santin AD
Front Oncol; 2020; 10():118. PubMed ID: 32117765
[No Abstract] [Full Text] [Related]
15. Development of a Novel Antibody-Drug Conjugate for the Potential Treatment of Ovarian, Lung, and Renal Cell Carcinoma Expressing TIM-1.
Thomas LJ; Vitale L; O'Neill T; Dolnick RY; Wallace PK; Minderman H; Gergel LE; Forsberg EM; Boyer JM; Storey JR; Pilsmaker CD; Hammond RA; Widger J; Sundarapandiyan K; Crocker A; Marsh HC; Keler T
Mol Cancer Ther; 2016 Dec; 15(12):2946-2954. PubMed ID: 27671527
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Antitumor Activity of an Anti-5T4 Antibody-Drug Conjugate in Combination with PI3K/mTOR inhibitors or Taxanes.
Shor B; Kahler J; Dougher M; Xu J; Mack M; Rosfjord E; Wang F; Melamud E; Sapra P
Clin Cancer Res; 2016 Jan; 22(2):383-94. PubMed ID: 26319086
[TBL] [Abstract][Full Text] [Related]
17. The role of lipolysis stimulated lipoprotein receptor in breast cancer and directing breast cancer cell behavior.
Reaves DK; Fagan-Solis KD; Dunphy K; Oliver SD; Scott DW; Fleming JM
PLoS One; 2014; 9(3):e91747. PubMed ID: 24637461
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
19. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma.
Lee JW; Han HD; Shahzad MM; Kim SW; Mangala LS; Nick AM; Lu C; Langley RR; Schmandt R; Kim HS; Mao S; Gooya J; Fazenbaker C; Jackson D; Tice DA; Landen CN; Coleman RL; Sood AK
J Natl Cancer Inst; 2009 Sep; 101(17):1193-205. PubMed ID: 19641174
[TBL] [Abstract][Full Text] [Related]
20. EV20‑sss‑vc/MMAF, an HER‑3 targeting antibody‑drug conjugate displays antitumor activity in liver cancer.
D'Agostino D; Gentile R; Ponziani S; Di Vittorio G; Dituri F; Giannelli G; Rossi C; Marzullo L; Giansanti F; De Laurenzi V; Iacobelli S; Ippoliti R; Capone E; Sala G
Oncol Rep; 2021 Feb; 45(2):776-785. PubMed ID: 33416143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
